Nivolumab antibody | AbD30258_hIgG1
A microtiter plate was coated overnight with nivolumab or human IgG4-Pro, human PD-1, pembrolizumab, natalizumab or trastuzumab at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human Anti-Nivolumab Antibody, clone AbD30258_hIgG1 (HCA301) titrated to the given concentrations in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with Human Anti-Nivolumab Antibody, clone AbD30255 (HCA299) at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of nivolumab. Detection was performed using HRP conjugated Human Anti-Nivolumab Antibody, clone AbD30258_hIgG1 (HCA301) at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with nivolumab at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human Anti-Nivolumab Antibodies, clone AbD30255_hIgG1 (HCA300, black line), clone AbD30258_hIgG1 (HCA301, red line), clone AbD30260_hIgG1 (HCA302, blue line) or clone AbD30264_hIgG1 (HCA303, pink line). Detection was performed using HRP conjugated nivolumab followed by QuantaBlu Fluorogenic Peroxidase Substrate. HRP conjugation of the nivolumab used in this assay was performed using a LYNX Rapid HRP Conjugation Kit (LNK002P). Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with recombinant human PD-1 at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of nivolumab (0.3 µg/ml), spiked with increasing concentrations of Human Anti-Nivolumab Antibody, clone AbD30258 (HCA301) in the monovalent Fab format was added. Free nivolumab, still capable of binding to the human PD-1 coated plate, was detected using a Mouse Anti-Human IgG (Fc) CH2 Domain:HRP Antibody (MCA647P) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human Anti-Nivolumab Antibody, clone AbD30258_hIgG1 (HCA301) at a concentration of 2 μg/ml in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate.
Human anti Nivolumab:HRP
Human Anti-Nivolumab Antibody is a recombinant, inhibitory, anti-idiotypic antibody in IgG1 format for use in drug level monitoring. It is labeled with HRP, and is recommended as the detection antibody in a PK bridging ELISA with HCA299 as capture antibody.
Human anti Nivolumab
Human Anti-Nivolumab Antibody is a recombinant, inhibitory, anti-idiotypic antibody in IgG1 format for use in drug level monitoring and immunogenicity testing. It can be used as a calibrator in an anti-drug antibody assay and detection antibody in a PK bridging ELISA with HCA299 for capture.
- Product Type
- Monoclonal Antibody
- Clone
- AbD30258_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Datasheet | MSDS | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|---|
| HCA301P | E | 0.1 mg | ||||
| HCA301 | E | 0.1 mg |
Human Anti-Nivolumab Antibody, clone AbD30258_hIgG1 is a paratope specific, inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug nivolumab. The antibody does not recognize recombinant human programmed cell death 1 (PD-1) or nivolumab in complex with recombinant human PD-1 and can be used to measure free nivolumab levels in serum from patients.
Clone AbD30258_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. A pair of anti-nivolumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in full immunoglobulin format, is recommended as the detection antibody paired with clone AbD30255 (HCA299) in monovalent Fab format as the capture antibody.
Nivolumab (Opdivo) is a fully human antibody (IgG4/kappa), with the heavy chain mutation S228P (IgG4-Pro). It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF. It is also approved for treatment of advanced non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin's lymphoma and advanced head and neck squamous cell carcinoma. Nivolumab is a checkpoint inhibitor and acts as an immuno-modulator by blocking ligand activation of PD-1 receptor on T cells, thereby activating T cells to attack the cancer. Nivolumab blocks PD-1 interaction with PD-1 ligand (PD-L1) and PD-1 ligand 2 (PD-L2).
View a summary of all anti-nivolumab antibodies
Clone AbD30258_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. A pair of anti-nivolumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in full immunoglobulin format, is recommended as the detection antibody paired with clone AbD30255 (HCA299) in monovalent Fab format as the capture antibody.
Nivolumab (Opdivo) is a fully human antibody (IgG4/kappa), with the heavy chain mutation S228P (IgG4-Pro). It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF. It is also approved for treatment of advanced non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin's lymphoma and advanced head and neck squamous cell carcinoma. Nivolumab is a checkpoint inhibitor and acts as an immuno-modulator by blocking ligand activation of PD-1 receptor on T cells, thereby activating T cells to attack the cancer. Nivolumab blocks PD-1 interaction with PD-1 ligand (PD-L1) and PD-1 ligand 2 (PD-L2).
View a summary of all anti-nivolumab antibodies
Product Details
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is conjugated to horseradish peroxidase (HRP) and supplied as liquid.
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Nivolumab
- Affinity
- The monovalent intrinsic affinity of AbD30258_hIgG1 was measured as KD = 2 nM by real time, label free molecular interaction analysis on immobilized nivolumab.
- Approx. Protein Concentrations
- Antibody concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 12 months from date of despatch
- Shelf Life
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Opdivo is a trademark of Bristol-Myers Squibb Company.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Opdivo is a trademark of Bristol-Myers Squibb Company.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Nivolumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- Clone AbD30258_hIgG1 can be used in a direct ELISA or as detection antibody for nivolumab in a bridging ELISA together with HCA299 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- Clone AbD30258_hIgG1 can be used in a direct or indirect ELISA or as detection antibody for nivolumab in a bridging ELISA together with HCA299 as the capture reagent. Furthermore, it may be used as a calibrator for the set-up of an anti-drug antibody assay.
Protocol: PK bridging ELISA to measure free drug and anti-drug antibody assay.
Copyright © 2018 Bio-Rad Antibodies (formerly AbD Serotec)
Negative Isotype Controls Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Recombinant Human IgG1 Lambda | HCA049 | 0.1 mg | E | ||
| Recombinant Human IgG1 Lambda | HCA049 | 0.1 mg | E |
Useful Reagents Available
| Description | Product Code | Pack Size | Applications | List Price | Quantity |
|---|---|---|---|---|---|
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Nivolumab | HCA299 | 0.1 mg | E | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | 3 Conjugations For 400µg Antibody | CJ | ||
| Hispec Assay Diluent | BUF049A | 50 ml | E IY | ||
| Human anti Nivolumab | HCA299 | 0.1 mg | E | ||
| LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | 3 Conjugations For 400µg Antibody | CJ | ||
| Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | 0.2 mg | C* E |
